Literature DB >> 3355902

Frequent association of idiopathic myelofibrosis with plasma cell dyscrasias.

U Dührsen1, M Uppenkamp, P Meusers, E König, G Brittinger.   

Abstract

In a retrospective analysis of 199 cases of myeloproliferative diseases a concomitant plasma cell dyscrasia was found in three out of 46 patients with idiopathic myelofibrosis. Chronic myeloid leukemia, polycythemia vera or unclassifiable myeloproliferative disorders were in no case associated with monoclonal gammopathy. One patient with idiopathic myelofibrosis had primarily coexistent IgG-lambda paraproteinemia and increasing osteolytic lesions; histologic evidence of multiple myeloma, however, was insufficient. In the second patient the interval between diagnosis of idiopathic myelofibrosis and IgG-kappa paraproteinemia was 11 years. After a stable period of 9 years' duration the paraprotein level rapidly increased, associated with depression of normal background immunoglobulins and progressive bone marrow failure. The exact nature of this patient's malignant plasma cell dyscrasia remained uncertain. In the third case benign monoclonal gammopathy of the IgM-lambda type was diagnosed 13 years after idiopathic myelofibrosis. A review of the literature confirms a remarkably high incidence of monoclonal gammopathies in idiopathic myelofibrosis. Benign monoclonal gammopathy seems to occur in at least 8% of the patients while only a few cases of concomitant multiple myeloma have been reported. It may be speculated that plasma cell dyscrasias in idiopathic myelofibrosis reflect involvement of the lymphoid lineage in the neoplastic stem cell disorder.

Entities:  

Mesh:

Year:  1988        PMID: 3355902     DOI: 10.1007/bf00320010

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  31 in total

1.  The myeloproliferative disorders with special reference to myelofibrosis.

Authors:  M S R HUTT; J L PINNIGER; G WETHERLEY-MEIN
Journal:  Blood       Date:  1953-04       Impact factor: 22.113

2.  Frequency of pathological proteins (M-components) om 6,995 sera from an adult population.

Authors:  U Axelsson; R Bachmann; J Hällén
Journal:  Acta Med Scand       Date:  1966-02

3.  Suppression of chronic lymphocytic leukemia by polycythemia vera.

Authors:  N J Vianna; L J Essman
Journal:  Cancer       Date:  1971-06       Impact factor: 6.860

4.  [Myeloma and myelofibrosis].

Authors:  J V Monplet; J L Vivancos; M G Basart; J M Arnau de Bolos
Journal:  Presse Med       Date:  1983-06-04       Impact factor: 1.228

5.  Philadelphia-chromosome-positive pre-B-cell leukemia presenting as blast crisis of chronic myelogenous leukemia.

Authors:  L B Vogler; W M Crist; P C Vinson; A Sarrif; M G Brattain; M S Coleman
Journal:  Blood       Date:  1979-11       Impact factor: 22.113

6.  Concomitant myelofibrosis with agnogenic myeloid metaplasia and malignant lymphoma.

Authors:  W H Jennings; C Y Li; J M Kiely
Journal:  Mayo Clin Proc       Date:  1983-09       Impact factor: 7.616

7.  IgD myeloma with myelofibrosis and amyloidosis.

Authors:  W C Udoji; S Pemmaraju
Journal:  Arch Pathol Lab Med       Date:  1977-01       Impact factor: 5.534

8.  Idiopathic myelofibrosis complicated by lymphoma. Report of two cases.

Authors:  R J Epstein; D E Joshua; H Kronenberg
Journal:  Acta Haematol       Date:  1985       Impact factor: 2.195

9.  Dual presentation of polycythaemia vera and lymphatic leukaemia.

Authors:  E Januszewicz; F C Firkin
Journal:  Aust N Z J Med       Date:  1980-04

10.  Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome.

Authors:  L Vandermolen; L Rice; E C Lynch
Journal:  Am J Med       Date:  1985-09       Impact factor: 4.965

View more
  2 in total

1.  Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).

Authors:  Sham Mailankody; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Neha Korde; Magnus Bjorkholm; Lynn R Goldin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

2.  Plasma cell leukemia with myelofibrosis.

Authors:  T Murayama; T Matsui; Y Hayashi; T Taniguchi; M Ito; T Natazuka; S Imoto; N Iwata; T Isobe; H Ito
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.